Research suggests optimal duration of dual antiplatelet therapy may vary depending on stent type

Source: Eur Heart J Area: News According to research published early online in the European Heart Journal, the optimal duration of dual antiplatelet therapy (DAPT) may differ depending on the type of stent implanted.   The authors note that this currently remains a controversial issue due to the lack of prospective, randomised data.  They conducted a pre-specified analysis of the PRODIGY study to assess device-specific outcomes relative to different duration of DAPT after everolimus- (EES), paclitaxel (PES), zotarolimus- (ZES-S) eluting, or bare metal stent (BMS) insertion.   The open-label PRODIGY study was designed to evaluate the efficacy and safety of prolonging the duration of clopidogrel therapy for up to 24 months in patients receiving various stents. A total of 2,013 patients undergoing elective, urgent or emergent coronary angioplasty were randomised to one of four stent types (EES, PES, ZES, BMS). Thirty-three (1.6%) patients died within 30 days and 10 withdrew consent, leaving ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news